Activity of gemcitabine in the treatment of patients with non-small cell lung cancer: A multicenter phase II study

Anti-Cancer Drugs

Volumn 8, Issue 6, 1997, Pages 574-581

  Yokoyama, Akira ^a   Nakai, Yushi ^b   Yoneda, Shuichi ^c   Kurita, Yuzo ^a   Niitani, Hisanobu ^d  

^a NIIGATA CANCER CENTER HOSPITAL   (Japan)

^b SENDAI KOUSEI HOSPITAL   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d Tokyo Cooperative Oncology Group   (Japan)

Author keywords

Gemcitabine; Multicenter; NSCLC; Nucleoside analog; Phase II study

Indexed keywords

GEMCITABINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTIC SHOCK; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANOREXIA; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0030875718     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199707000-00004     Document Type: Article

References (25)

1. Hertel LW, Kroin JS, Misner JW, et al. Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleotides. J Org Chem 1988; 53: 2406-9.
2. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosy cytosine. Cancer Res 1988; 48: 4024-31.
3. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-7.
4. Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, Grindey GB, Von Hoff DD. Activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units. Anti-Cancer Drugs 1992; 3: 143-6.
5. Bhalla K, Holladay C, Lutzky J, et al. Deoxycytidine protests normal bone marrow progenitors against ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells. Gynecol Oncol 1992; 45: 32-9.
6. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of Gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50: 4417-22.
7. Gandhi V, Plunkett W. Modulatory activity of 2′,2′-difluorodeoxycytidine on phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 1990; 50: 3675-80.
8. 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine(dFdC) in two small cell lung cancer xenografts. Ann Oncol 1993; 4: 157-60.
9. Fujita M, Fujita F, Inaba H, Taguchi T. Antitumor activity of LY188011, a new deoxycytidine analog against human cancers xenografted into nude mice. Jpn J Cancer Chemother 1994; 21: 517-23.
10. Taguchi T, Furuse K, Fukuoka M, et al. LY188011 phase I study. Jpn J Cancer Chemother 1996; 23: 1011-8.
11. Fukuoka M, Noda K, K Hasegawa, et al. An early-phase II study of Gemcitabine hydrochloride. Jpn J Cancer Chemother 1996; 23: 1813-24.
12. The Criteria of the Adverse Reaction Assessment List of Japan Society for Cancer Therapy. J Jpn Soc Cancer Ther 1986; 21: 943-53.
13. O'Rourke TJ, Brown TD, Harvin K, et al. Phase I clinical trial of gemcitabine given as an intravenous bolus on five consecutive days. Eur J Cancer 1994; 30: 417-8.
14. Poplin E, Corbett T, Flaherty L, et al. Difluorodeoxycytidine (dFdC) gemcitabine: a phase I study. Invest New Drugs 1992; 10: 165-70.
15. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8.
16. Anderson H. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1821-6.
17. Abratt RF, Bezwoda WR, Falkson G. Hacking D. Rugg TA. Efficacy and Safety Profile of Gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1535-40.
18. Lund B, Ryberg M, Meidahl-Petersen P, Anderson LH. Thatcher N, Dombernowsky P. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. Ann Oncol 1994; 5: 852-3.
19. Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine (days 1, 8, 15) with monthly cisplatin (day 15): active combination chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 1997; 15: 744-9.
20. Crinò L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer (NSCLC). A phase II study. J Clin Oncol 1997; 15: 297-303.
21. Sandier A, Crin L, Steward WP, Abratt RP Extended survival in stage IH and IV non-small cell lung cancer (NSCLC) patients treated with gemcitabine plus monthly cisplatin. Ann Oncol 1996; 7 (suppl 5, abstr 435P).
22. Shepherd FA. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer: usefulness of mathematic modelling to determine maximum tolerated dose, J Clin Oncol 1996; 14: 1656-62.
23. Steward WP, Dunlop DJ, Dabouis G, Lacroix H, Talbot D. Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer - preliminary results. Semin Oncol 1996; 23 (suppl 10): 43-7.
24. Carmichael J, Allerheiligen S, Walling J. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer (NSCLC). Semin Oncol 1996; 23 (suppl 10): 55-9.
25. Manegold CH, Eberhard W, Wilke H, et al. Phase II study of gemcitabine (GEM) and ifosfamide (IFO) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1996; 15: 380 (abstr 1137).